PROF. DR. SEE MEE HOONG
Department of Surgery
Faculty of Medicine
smhoong76um.edu.myView CV | |
Personal Homepage | |
Publons | |
Scopus Link | |
PubMed Link | |
Biography | |
Professor Dr. See Mee-Hoong is an esteemed senior lecturer at the University of Malaya and a dedicated Consultant Oncoplastic Breast Surgeon at the University Malaya Medical Center (UMMC). Graduating with her undergraduate medical degree from UPM in 2003, she continued her academic excellence by earning her Master's Degree in Surgery (General) from the University of Malaya in May 2011 and obtained her fellowship in Breast Oncoplastic training from 2012 to 2015 in Universiti Malaya and Mahidol University, Thailand. Currently, she is nationally registered as a Breast Oncoplastic Surgeon. Her commitment to medical education and clinical practice led her to join the University Malaya Medical Faculty in 2012, where she specialized as a clinical lecturer focusing on Breast Oncoplastic Surgery. Dr. See further honed her skills as an honorary fellow at Siriraj Hospital, Mahidol University, Bangkok, Thailand in 2013, and later completed advanced training in minimally invasive techniques and Cryoablation at Kameda Medical Centre under Dr. Eisuke Fukuma in 2016. In 2022, Dr. See underwent robotic breast surgery training at Chang Hua Christian Medical Centre, Taichung, Taiwan. She has since pioneered minimally invasive breast surgeries at UMMC, offering patients the benefits of early recovery, smaller scars, better aesthetic outcomes, and comparable oncological results. She has also been elected as a council member of Breast Surgical International and ISAES in 2024, marking significant milestones in her leadership and expertise. She is set to introduce robotic nipple-sparing mastectomy and immediate reconstruction at UMMC in 2025. Dr. See serves as the clinical head of the Breast Surgery Unit at UMMC (currently know as Breast and Endocrine Unit), where she leads a team committed to providing high-quality care to patients. Her research interests span Clinical Breast Surgical Oncology, including minimally invasive breast surgeries and Enhanced Recovery After Surgery (ERAS) in Breast Reconstruction. She has also led the development of Decision Aids in Breast Reconstruction and is actively involved in clinical trials focused on breast cancer treatments, including Minimally Invasive and Oncoplastic Surgery and Intraoperative Radiotherapy (TARGIT B Trial). A driving force in Dr. See's work is her passion for uniting Southeast Asian and Asian breast surgeons through knowledge sharing and collaboration. She spearheads this effort through the Asian Breast Surgery Forum (ABSF - an ECHO Project), which she leads in collaboration with the University of New Mexico’s Project ECHO®. The forum connects 12 Asian countries, fostering the exchange of expertise and best practices in breast surgery. Dr. See is actively involved in various international surgical organizations, including the International Oncoplastic Breast Surgery (IOPBS) and the International Endoscopic and Robotic Breast Surgery (IERBS) societies, contributing to the global advancement of breast surgical practices. Currently, Dr. See serves as the deputy Head of Visibility Unit in the Faculty of Medicine at the University of Malaya. Her leadership and vision continue to impact the field of breast surgery, both regionally and globally, as she remains dedicated to enhancing surgical standards and patient outcomes
|
Publication
Finance
Project Title | Progress | Status |
---|---|---|
The Development Of Artificial Intelligence-based Techniques In Precision Surgical Planning For Breast Reconstruction |
|
end |
An In-vivo Optical Fibre Radiation Dosimetry System For The Intrabeamic System In Breast Cancer Patients Undergoing Breast Conserving Surgery Intraoperative Radiotheraphy |
|
end |
Determinants Of Adherence To Therapies Among Malaysian Women With Breast Cancer: Mybcc Cohort |
|
end |
This information is generated from Research Grant Management System |
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer
Age-specific breast and ovarian cancer risks associated with germline BRCA1 or BRCA2 pathogenic variants – an Asian study of 572 families
Trends in Presentation, Management, and Survival of Women With Breast Cancer in a Multiethnic, Middle-Income Asian Setting
Clustering of HR + /HER2− breast cancer in an Asian cohort is driven by immune phenotypes
PINK AGENT : STORIES FROM PATIENTS
Pink Agent